Literature DB >> 25188495

Fatal meningococcal disease in a laboratory worker--California, 2012.

Channing D Sheets, Kathleen Harriman, Jennifer Zipprich, Janice K Louie, William S Probert, Michael Horowitz, Janice C Prudhomme, Deborah Gold, Leonard Mayer.   

Abstract

Occupationally acquired meningococcal disease is rare. Adherence to recommendations for safe handling of Neisseria meningitidis in the laboratory greatly reduces the risk for transmission to laboratory workers. A California microbiologist developed fatal serogroup B meningococcal disease after working with N. meningitidis patient isolates in a research laboratory (laboratory A). The California Department of Public Health (CDPH), the local health department, the California Division of Occupational Safety and Health (CalOSHA), and the federal Occupational Safety and Health Administration (OSHA) collaborated on an investigation of laboratory A, which revealed several breaches in recommended laboratory practice for safe handling of N. meningitidis, including manipulating cultures on the bench top. Additionally, laboratory workers had not been offered meningococcal vaccine in accordance with Advisory Committee on Immunization Practices (ACIP) recommendations and CalOSHA Aerosol Transmissible Diseases Standard requirements. In accordance with OSHA and CalOSHA regulations, laboratory staff members must receive laboratory biosafety training and use appropriate personal protective equipment, and those who routinely work with N. meningitidis isolates should receive meningococcal vaccine.

Entities:  

Mesh:

Year:  2014        PMID: 25188495      PMCID: PMC5779447     

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


Occupationally acquired meningococcal disease is rare (1). Adherence to recommendations for safe handling of Neisseria meningitidis in the laboratory greatly reduces the risk for transmission to laboratory workers (2). A California microbiologist developed fatal serogroup B meningococcal disease after working with N. meningitidis patient isolates in a research laboratory (laboratory A). The California Department of Public Health (CDPH), the local health department, the California Division of Occupational Safety and Health (CalOSHA), and the federal Occupational Safety and Health Administration (OSHA) collaborated on an investigation of laboratory A, which revealed several breaches in recommended laboratory practice for safe handling of N. meningitidis, including manipulating cultures on the bench top. Additionally, laboratory workers had not been offered meningococcal vaccine in accordance with Advisory Committee on Immunization Practices (ACIP) recommendations and CalOSHA Aerosol Transmissible Diseases Standard requirements (3,4). In accordance with OSHA and CalOSHA regulations, laboratory staff members must receive laboratory biosafety training and use appropriate personal protective equipment, and those who routinely work with N. meningitidis isolates should receive meningococcal vaccine.

Case Report

On the evening of Friday, April 27, 2012, a microbiologist aged 25 years had onset of headache, fever, neck pain, and stiffness. The following morning, April 28, he was transported by automobile to the emergency department at hospital A, where he was employed in laboratory A as a researcher. While on the way to the hospital he lost consciousness. Upon arrival, the patient was noted to have a petechial rash, was suspected of having meningococcal disease, and was treated with ceftriaxone. He later had a respiratory arrest. Attempted resuscitation was unsuccessful, and he was declared dead approximately 3 hours after his arrival. On the day of the patient’s death, hospital A notified the local health department and CDPH of the case of suspected meningococcal disease. On April 29, hospital A notified OSHA, which notified CalOSHA that the deceased had worked in a laboratory conducting N. meningitidis vaccine research. Hospital A evaluated potentially exposed emergency department staff members and research laboratory employees; all persons found to have been exposed were immediately assessed for symptoms of meningococcal disease and offered postexposure chemoprophylaxis. Laboratory A voluntarily closed on April 30. No additional cases of meningococcal disease were identified among emergency department or laboratory staff members. The local health department identified other close contacts of the patient and ensured that they received postexposure chemoprophylaxis. Blood and tissue specimens from the patient were sent to the CDPH Microbial Diseases Laboratory for isolation and serogroup identification. N. meningitidis serogroup B was identified in the clinical specimens by polymerase chain reaction. The patient had worked with N. meningitidis serogroup B isolates in the weeks and days before his death.

Investigation Findings

CalOSHA, OSHA, and CDPH initiated an investigation. Laboratory A was inspected, and employees were interviewed about their training as well as laboratory practices and protocols and were asked to demonstrate how procedures were performed. Multiple breaches in recommended laboratory safety practices were identified (Tables 1 and 2), including manipulation of N. meningitidis isolates on an open laboratory bench (2,5). The inspection team made recommendations for safe handling of N. meningitidis isolates and use of appropriate personal protective equipment. Laboratory A microbiologists working with N. meningitidis isolates had not been offered quadrivalent meningococcal vaccine, as recommended by ACIP (4). At the conclusion of the investigation, OSHA issued three citations classified as serious for failure to protect laboratory workers.
TABLE 1

Selected breaches in recommended laboratory practices for Neisseria meningitidis that were observed by an inspection team after the death of a laboratory worker — California, 2012

ActivityObserved practiceRecommended practice
Flaming of Gram stain slideSlide not allowed to completely air dry before flaming.This activity was conducted on the open bench.Allow the slide to air dry before applying fixation.Use alternative methods (e.g., alcohol fixation) in the BSC.
Plate spreadingA disposable plate spreader was used to saturate the plate with the organism.The activity was conducted on the open bench.A cotton-tipped swab could be used instead of a plastic spreader to reduce the amount of generated aerosol.If plate spreading is necessary, it should be conducted in the BSC.
Plate scrapingA disposable plastic plate scraper was used to harvest the bacteria on the plate.This activity was conducted on the open bench.Plate scraping is not recommended, but if necessary should be performed in the BSC with appropriate PPE.
Flaming loopsTransfer loops used to inoculate media were flamed on the open bench.Open flames are no longer universally recommended. Electric furnaces are an alternative.Disposable transfer loops used in the BSC are preferable.
Re-suspension of solutionA solution containing substantial concentrations of viable organism was inoculated with an inactivating enzyme.The solution was vigorously pipetted to create a homogenous solution. This activity occurred 10 minutes into the enzymatic reaction.This activity should be performed in the BSC.Manufacturer recommends a 20–30 minute treatment time for the enzymatic reaction.
Opening discard binThe biohazard discard bin lid was foot-pedal operated and opening can rapidly generate an aerosol.Infectious material should be manipulated in the BSC. Discards should be disposed of in a biohazard bag in the BSC. Biohazard bags should be sealed and wiped down before they are transferred to the biohazard bin outside the BSC.
Discarding plate scraper and spreaderMicrobiologists dropped contaminated scrapers and spreaders into an open discard bin located on the floor after working with them on the open bench, potentially generating aerosols.Spreaders and scrapers should only be used in the BSC. Contaminated spreaders and scrapers should be placed in either a discard pan or biohazard bag. The bag or container should be sealed or covered with a lid and wiped down before removal from the BSC.

Abbreviations: BSC = biological safety cabinet; PPE = personal protective equipment.

TABLE 2

Selected breaches in recommended personnel protective equipment practices for Neisseria meningitidis that were observed by an inspection team after the death of a laboratory worker — California, 2012

Personal protective equipmentObserved practiceRecommended practice
Laboratory coatCloth laboratory coats were worn. Coats were not routinely decontaminated.Disposable closed front laboratory coats are preferred. If reusable coats are used, they should be routinely decontaminated and then laundered.
GlovesMicrobiologists wore a single pair of latex gloves while working on the open bench and in the BSC.BSL-2+ practices warrant using double gloves. The outer gloves should be removed and placed in the biohazard bag or pan in the BSC. Then inner gloves can be removed outside the BSC. Microbiologists should immediately wash their hands upon removing inner gloves.
Eye protectionMicrobiologists wore their regular prescription eye glasses for eye protection.Regular eye glasses are not considered eye protection. Wrap-around eye protection, goggles, or face shields are preferred.
Respiratory protectionLaboratory staff only wore N95 respirators while cleaning up spills.BSL-2+ practices warrant the use of a respirator that is at least as protective as a fit-tested NIOSH-certified N95 filtering facepiece respirator particularly when culturing large volumes of N. meningitidis.

Abbreviations: BSC = biological safety cabinet; BSL = biosafety level; NIOSH = National Institute for Occupational Safety and Health.

Discussion

Although occupationally acquired meningococcal disease is rare, it is a known risk among microbiologists who work with N. meningitidis isolates (6–8). Investigations of laboratory-acquired cases of meningococcal disease in the United States have demonstrated a many-fold higher attack rate for microbiologists compared with the U.S. general population aged 30–59 years and a case fatality rate of 50%, more than triple the 12%–15% case fatality rate associated with disease in the general population (9). In almost all cases, infected microbiologists had manipulated sterile-site isolates on an open laboratory bench outside of a biosafety cabinet (2,6). Manipulating N. meningitidis isolates outside a biosafety cabinet is known to be associated with a high risk for contracting meningococcal disease (7). To decrease the risk of transmission to laboratory workers handling invasive N. meningitidis strains (serogroups A, B, C, Y, and W), CDC recommends the use of enhanced biosafety level two (BSL-2) containment practices, where BSL-2 requirements are met and some BSL-3 practices also are adopted (2). Updated recommendations for microbiologists manipulating N. meningitidis strains were published in January 2012 as a supplement to the Biosafety in Microbiological and Biomedical Laboratories guide and include the use of a nonrecirculating biosafety cabinet and the following personal protective equipment: disposable closed front laboratory coat, double gloves, fit-tested N95 filtering facepiece or higher level respiratory protection, and eye protection (2,5). In California, personnel using respirators also must be enrolled in a respiratory protection program (10). What is already known on this topic? Working with Neisseria meningitidis isolates without adequate protection on the open laboratory bench can result in aerosol transmission of the bacteria. Meningococcal disease is severe and can be fatal. Among laboratory-acquired meningococcal disease cases, the case fatality rate was 50% in one study, significantly higher than the case fatality rate in the general population. The Advisory Committee on Immunization Practices (ACIP) has published immunization guidelines for laboratory workers who are routinely exposed to isolates of N. meningitidis. What is added by this report? A laboratory researcher who worked with N. meningitidis died from serogroup B meningococcal disease. An investigation identified deficiencies in training and practices in laboratory A, including manipulating cultures outside of a biosafety cabinet. Additionally, laboratory workers who routinely worked with N. meningitidis had not been vaccinated in accordance with current ACIP recommendations. What are the implications for public health practice? Adequate safety training for laboratory personnel, adherence to recommendations for safe handling of N. meningitidis isolates, and vaccination (where indicated) are necessary to reduce the risk for disease among laboratory workers. Although this fatal case of serogroup B meningococcal disease was not vaccine-preventable by meningococcal vaccines currently licensed in the United States, licensed vaccines to protect against serogroup A, C, Y, and W-135 disease are available. ACIP recommends meningococcal vaccination for microbiologists who are routinely exposed to isolates of N. meningitidis (3,4). The CalOSHA Aerosol Transmissible Diseases Standard also requires that California employers offer all vaccinations as recommended by applicable public health guidelines for specific laboratory operations (1,4). A serogroup B vaccine (Bexsero, Novartis) was licensed in Europe, Australia, and Canada in 2013 and has received a “breakthrough therapy” designation from the Food and Drug Administration. Employers should be familiar with laboratory biosafety recommendations and ensure that a laboratory biosafety program is in place. Employers also should ensure that laboratory staff are trained, adhere to recommended biosafety practices and procedures, and are offered recommended vaccines.
  7 in total

1.  Risk of laboratory-acquired meningococcal disease.

Authors:  R Boutet; J M Stuart; E B Kaczmarski; S J Gray; D M Jones; N Andrews
Journal:  J Hosp Infect       Date:  2001-12       Impact factor: 3.926

2.  Guidelines for safe work practices in human and animal medical diagnostic laboratories. Recommendations of a CDC-convened, Biosafety Blue Ribbon Panel.

Authors:  J Michael Miller; Rex Astles; Timothy Baszler; Kimberle Chapin; Roberta Carey; Lynne Garcia; Larry Gray; Davise Larone; Michael Pentella; Anne Pollock; Daniel S Shapiro; Elizabeth Weirich; Danny Wiedbrauk
Journal:  MMWR Suppl       Date:  2012-01-06

Review 3.  Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures.

Authors:  Tjeerd G Kimman; Eric Smit; Michèl R Klein
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

4.  Laboratory-acquired meningococcemia--California and Massachusetts.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1991-01-25       Impact factor: 17.586

5.  Laboratory-acquired meningococcal disease--United States, 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-02-22       Impact factor: 17.586

Review 6.  Assessing the risk of laboratory-acquired meningococcal disease.

Authors:  James J Sejvar; David Johnson; Tanja Popovic; J Michael Miller; Frances Downes; Patricia Somsel; Robbin Weyant; David S Stephens; Bradley A Perkins; Nancy E Rosenstein
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

7.  Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Amanda C Cohn; Jessica R MacNeil; Thomas A Clark; Ismael R Ortega-Sanchez; Elizabeth Z Briere; H Cody Meissner; Carol J Baker; Nancy E Messonnier
Journal:  MMWR Recomm Rep       Date:  2013-03-22
  7 in total
  4 in total

Review 1.  Biological Risks and Laboratory-Acquired Infections: A Reality That Cannot be Ignored in Health Biotechnology.

Authors:  Ana Cláudia Coelho; Juan García Díez
Journal:  Front Bioeng Biotechnol       Date:  2015-04-28

2.  Case Investigations of Infectious Diseases Occurring in Workplaces, United States, 2006-2015.

Authors:  Chia-Ping Su; Marie A de Perio; Kristin J Cummings; Anna-Binney McCague; Sara E Luckhaupt; Marie Haring Sweeney
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883

Review 3.  Occupational Health Update: Focus on Preventing the Acquisition of Infections with Pre-exposure Prophylaxis and Postexposure Prophylaxis.

Authors:  David J Weber; William A Rutala
Journal:  Infect Dis Clin North Am       Date:  2016-09       Impact factor: 5.982

Review 4.  Zika Virus Infection During Research Vaccine Development: Investigation of the Laboratory-Acquired Infection via Nanopore Whole-Genome Sequencing.

Authors:  Eunsik Bang; Sujin Oh; Ho Eun Chang; Il Seob Shin; Kyoung Un Park; Eu Suk Kim
Journal:  Front Cell Infect Microbiol       Date:  2022-03-07       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.